Merck Scores First Win in $1.3B Ophthalmology Bet
Merck's $1.3 billion upfront bet on EyeBio in 2024 is starting to pay off.
The New Jersey drug giant, attempting to expand its presence in ophthalmology, made this significant investment two years ago.
As a result of this partnership, Merck has achieved its first success in the field.